Rather than applying a blanket “anti immunomodulatory” strategy, clinicians should prioritize drugs with proven efficacy and mechanistic rationale, specifically NLRP3 inflammasome inhibitors (e.g., colchicine) and IL-1β pathway inhibitors (e.g., canakinumab) should be considered for secondary prevention in CHD patients. This evidence concerns the gene NLRP3 and coronary artery disorder.